Predictive value of interim 18F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment-Reference-Cited by-同舟云学术

Predictive value of interim 18F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment

Published:2013-10 Issue:10 Volume:34 Page:946-952
ISSN:0143-3636
Container-title:Nuclear Medicine Communications
language:en
Short-container-title:

Author:

González-Barca Eva,Canales Miguel,Cortés Montse,Vidal M. Jesus,Salar Antonio,Oriol Albert,Bargay Joan,Bello José L.,Sánchez José J.,Tomás José F.,Donato Eva,Ferrer Secundino,Caballero Dolores

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Radiology Nuclear Medicine and imaging,General Medicine

Reference5 articles.

1. New approach to classifying non-Hodgkins lymphomas: clinical features of the major histologic subtypes. Non-Hodgkins Lymphoma Classification Project.;Armitage;J Clin Oncol,1998

2. A predictive model for aggressive non-Hodgkins lymphoma. The International Non-Hodgkins Lymphoma Prognostic Factors Project.;Shipp;N Engl J Med,1993

3. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkins disease.;Kostakoglu;J Nucl Med,2002

4. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma.;Mikhaeel;Ann Oncol,2005

5. High incidence of false-positive PET scans in patients with aggressive non-Hodgkins lymphoma treated with rituximab-containing regimens.;Han;Ann Oncol,2009

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Значение ПЭТ, совмещенной с КТ, при диффузной В-крупноклеточной лимфоме: история вопроса, эволюция представлений и современные возможности метода (обзор литературы);Clinical Oncohematology;2024-02-20

2. PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial design;Leukemia & Lymphoma;2022-07-11

3. [18F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studies;European Journal of Nuclear Medicine and Molecular Imaging;2021-09-04

4. Cualificación de fantomas 18F para ensayos clínicos con imagen PET/TC-18F-FDG adoptada por GELTAMO (Grupo Español de Linfomas/Trasplante Autólogo de Médula Ósea);Revista Española de Medicina Nuclear e Imagen Molecular;2021-05

5. The 18 F phantom clinical trials qualification for 18F-FDG-PET scanning adopted by GELTAMO (Grupo Español de Linfomas/Trasplante Autologo de Médula Ósea);Revista Española de Medicina Nuclear e Imagen Molecular (English Edition);2021-05